Get the Stockscreener App
3.89
0.52%
0.02
After Hours:
4.08
0.19
+4.88%
Maxcyte Inc stock is traded at $3.89, with a volume of 411.20K.
It is up +0.52% in the last 24 hours and down -9.95% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$3.87
Open:
$3.85
24h Volume:
411.20K
Relative Volume:
0.98
Market Cap:
$403.02M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-12.16
EPS:
-0.32
Net Cash Flow:
$-25.39M
1W Performance:
-1.77%
1M Performance:
-9.95%
6M Performance:
-7.16%
1Y Performance:
+24.68%
1-Day Range:
$3.79
$3.975
1-Week Range:
$3.78
$3.99
52-Week Range:
$2.45
$5.545
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
Maxcyte director Johnston sells shares worth over $11,000 - Investing.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72 - MarketBeat
MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72 - Defense World
MaxCyte shares retain buy rating on strong cell therapy platform By Investing.com - Investing.com Canada
MaxCyte shares retain buy rating on strong cell therapy platform - Investing.com
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth - Yahoo Finance
Massachusetts Financial Services Co. MA Has $1.96 Million Stake in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases - MSN
Massachusetts Financial Services Co. MA Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases - Head Topics
MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases - News-Medical.Net
BlackRock Ups Stake in MaxCyte to 9.75% - TipRanks
Rx Rundown: MaxCyte, Roche, and more - MM+M Online
MaxCyte Signs Strategic Platform License With Kamau Therapeutics To Accelerate the Development of Cell Therapies for Genetic Diseases - Technology Networks
Bank of New York Mellon Corp Has $1.66 Million Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte and Kamau Therapeutics sign platform license agreement - Pharmaceutical Technology
MaxCyte and Kamau Therapeutics sign platform license agreement - Yahoo Finance
MaxCyte enters licence agreement with Kamau Therapeutics - ShareCast
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases - ForexTV.com
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases - StockTitan
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development - The Bakersfield Californian
MaxCyte Partners with Kamau Therapeutics to Advance Gene Therapies - TipRanks
MaxCyte (LON:MXCT) Shares Pass Below 50 Day Moving Average of $330.81 - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Grows Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Director Executes Options, Sells Shares - TipRanks
MaxCyte Announces Participation in Bioprocessing Conference - TipRanks
MaxCyte (LON:MXCT) Stock Price Passes Below 50-Day Moving Average of $332.41 - MarketBeat
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference - ForexTV.com
Insider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 29,767 Shares of Stock - MarketBeat
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference - StockTitan
MaxCyte Inc [MXCT] Officer makes an insider purchase of 143,067 shares worth 0.62 million. - Knox Daily
Exercise of options and PDMR dealing - ShareCast
MaxCyte Director Executes Stock Options and Sells - TipRanks
MaxCyte director Johnston sells shares worth over $12,000 - Investing.com India
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
MaxCyte director Johnston sells shares worth over $12,000 - Investing.com
SG Americas Securities LLC Sells 11,194 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Recent Insider Activity Suggests Potential Gains for MaxCyte Inc (MXCT) - Knox Daily
MaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five years - Yahoo Finance
Price T Rowe Associates Inc. MD Has $106,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (LON:MXCT) Stock Price Crosses Below 50-Day Moving Average of $345.70 - Defense World
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? - MSN
Vanguard Group Inc. Has $22.40 Million Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
FY2024 EPS Estimates for MaxCyte, Inc. (NASDAQ:MXCT) Lifted by William Blair - Defense World
FY2024 Earnings Forecast for MaxCyte, Inc. (NASDAQ:MXCT) Issued By William Blair - MarketBeat
MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Market Resilience: MaxCyte Inc (MXCT) Finishes Weak at 4.08, Down -8.31 - The Dwinnex
MaxCyte Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
EVP, GLOBAL SALES Ross Thomas M. sale 17,857 shares of MaxCyte Inc [MXCT] - Knox Daily
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):